Full Press Release Details
REGENERON REPORTS PHASE II RESULTS FOR IL-1 TRAP CLINICAL PROGRAM IN RHEUMATOID ARTHRITIS IL-1 Trap Phase II Study Demonstrates Clinical Activity and Favorable Safety and Tolerability Profile.
REGN
REGENERON REPORTS PHASE II RESULTS FOR IL-1 TRAP CLINICAL PROGRAM IN RHEUMATOID ARTHRITIS IL-1 Trap Phase II Study Demonstrates Clinical Activity and Favorable Safety and Tolerability Profile
Key Takeaway: REGENERON REPORTS PHASE II RESULTS FOR IL-1 TRAP CLINICAL PROGRAM IN RHEUMATOID ARTHRITIS IL-1 Trap Phase II Study Demonstrates Clinical Activity and Favorable Safety and Tolerability Profile
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+42%
120-day peak, hindsight
Typical move
2.7%
average across 15 past catalysts
Lead asset
REGN7508
Phase 3 · Venous Thromboembolism